Upgrade to SI Premium - Free Trial

Cellectis (CLLS)

1.61 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/9/26)
- M&A (Rumor)

Latest Headlines

Barclays Double Downgrades Cellectis (CLLS) to Underweight September 16, 2026 3:49 AM - StreetInsider Cellectis (CLLS) PT Lowered to $3 at Wells Fargo September 15, 2026 6:34 AM - StreetInsider Citizens Downgrades Cellectis (CLLS) to Market Perform September 15, 2026 3:16 AM - StreetInsider Cellectis (CLLS) PT Lowered to $8 at Baird September 14, 2026 8:58 AM - StreetInsider Cellectis (CLLS) Tops Q2 EPS by 4c August 6, 2026 5:53 PM - StreetInsider Prolynx names CFO and CSO to advance obesity drug portfolio July 15, 2026 8:01 AM - StreetInsider Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio July 15, 2026 8:00 AM - Globe NewsWire Full Article List